Table 3.
Univariate analyses of predictors of disease‐free survival among 86 patients with colorectal cancer liver metastases
| Factor | Univariate analysis | |
|---|---|---|
| Hazard ratio (95% CI) | P‐value | |
| Age, years | ||
| ≥64 | 1.364 (0.842–2.305) | 0.197 |
| <64 | ||
| Gender | ||
| Female | 1.222 (0.703–2.211) | 0.451 |
| Male | ||
| Primary site | ||
| Rectum | 1.119 (0.673–1.886) | 0.65 |
| Colon | ||
| TNM stage | ||
| III, IV | 1.407 (0.809–2.411) | 0.231 |
| I, II | ||
| Timing of operation | ||
| Metachronous | 0.846 (0.504–1.391) | 0.493 |
| Synchronous | ||
| Size of tumor, mm | ||
| ≥50 | 1.440 (0.748–3.207) | 0.239 |
| <50 | ||
| Number of liver metastases | ||
| Multiple | 1.851 (1.164–3.189) | 0.011 |
| Single | ||
| Liver metastasis grade | ||
| B, C | 1.943 (1.233–3.400) | 0.006 |
| A | ||
| Serum CEA, ng/mL | ||
| ≥20 | 1.300 (0.791–2.235) | 0.283 |
| <20 | ||
| Serum CA19‐9, ng/mL | ||
| ≥37 | 1.709 (1.067–3.066) | 0.028 |
| <37 | ||
| DYRK2 expression | ||
| Low | 1.560 (1.003–2.765) | 0.049 |
| High | ||
CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CI, confidence interval; DYRK2, dual‐specificity tyrosine‐regulated kinase 2.